Posted: 3 days, 18 hours ago / Oct. 21, 2025 2:03 p.m. UTC
UnitedHealthcare Deal Sparks Buzz: Recent chatter on X about Plus Therapeutics (PSTV) has surged following the announcement of a national coverage agreement with UnitedHealthcare for its CNSide cancer diagnostic test. Many users are thrilled about the deal’s reach, covering over 51 million individuals, and its potential to boost the company’s market presence. The stock price has seen notable movement, fueling further speculation on future growth.
CNSide Platform Progress: Discussions also highlight the latest updates on the CNSide diagnostic platform, with posts on X noting its commercial rollout and CLIA accreditation as significant milestones. Enthusiasm surrounds the platform’s potential to improve detection of central nervous system metastases. Some users are optimistic about upcoming quarterly revenue reports reflecting these advancements.
Analyst Upgrades Add Fuel: Adding to the excitement, recent analyst upgrades and raised price targets for PSTV have been a hot topic on X. Several posts mention positive ratings like ‘Buy’ and ‘Strong-Buy’ from firms, with targets ranging widely, which has kept the conversation lively. This mix of news keeps the community engaged and watching closely.
Note: This discussion summary was generated from an AI condensation of post data.
Plus Therapeutics Insider Trading Activity
Plus Therapeutics insiders have traded $PSTV stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:
- ROBERT P LENK purchased 110,000 shares for an estimated $53,779
To track insider transactions, check out Quiver Quantitative’s insider trading dashboard.
Plus Therapeutics Hedge Fund Activity
We have seen 11 institutional investors add shares of Plus Therapeutics stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 117,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $40,850
- HRT FINANCIAL LP removed 102,065 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $35,498
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 80,505 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $27,999
- UBS GROUP AG added 54,201 shares (+162.1%) to their portfolio in Q2 2025, for an estimated $18,851
- VIRTU FINANCIAL LLC removed 40,030 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,922
- GOLDMAN SACHS GROUP INC added 26,753 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,304
- MILLENNIUM MANAGEMENT LLC added 24,233 shares (+inf%) to their portfolio in Q2 2025, for an estimated $8,428
To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard.
Plus Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a “Buy” rating on 10/06/2025
- D. Boral Capital issued a “Buy” rating on 09/25/2025
- Maxim Group issued a “Buy” rating on 08/18/2025
- HC Wainwright & Co. issued a “Buy” rating on 06/27/2025
To track analyst ratings and price targets for Plus Therapeutics, check out Quiver Quantitative’s $PSTV forecast page.
Plus Therapeutics Price Targets
Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Edward Woo from Ascendiant Capital set a target price of $21.0 on 10/06/2025
- Jason Kolbert from D. Boral Capital set a target price of $5.0 on 09/25/2025
- Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025
- Sean Lee from HC Wainwright & Co. set a target price of $3.0 on 06/27/2025
This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
